226 related articles for article (PubMed ID: 30072307)
21. Association between acid-suppressive drug use and atopic dermatitis in patients with upper gastrointestinal diseases: A population-based retrospective cohort study.
Lin HC; Chen YY; Lin HL; Uang YS; Ho Y; Wang LH
J Clin Pharm Ther; 2021 Jun; 46(3):786-793. PubMed ID: 33403692
[TBL] [Abstract][Full Text] [Related]
22. Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study.
Sáez ME; González-Pérez A; Gaist D; Johansson S; Nagy P; García Rodríguez LA
Epilepsy Behav; 2016 Sep; 62():72-80. PubMed ID: 27450309
[TBL] [Abstract][Full Text] [Related]
23. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study.
Andersen AB; Erichsen R; Farkas DK; Mehnert F; Ehrenstein V; Sørensen HT
Aliment Pharmacol Ther; 2012 May; 35(10):1190-8. PubMed ID: 22443179
[TBL] [Abstract][Full Text] [Related]
24. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
25. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
26. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors and risk of colorectal cancer.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):111-118. PubMed ID: 34210775
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
29. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
30. Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.
Tai SY; Chien CY; Wu DC; Lin KD; Ho BL; Chang YH; Chang YP
PLoS One; 2017; 12(2):e0171006. PubMed ID: 28199356
[TBL] [Abstract][Full Text] [Related]
31. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
32. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
Gomm W; von Holt K; Thomé F; Broich K; Maier W; Fink A; Doblhammer G; Haenisch B
JAMA Neurol; 2016 Apr; 73(4):410-6. PubMed ID: 26882076
[TBL] [Abstract][Full Text] [Related]
33. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study.
Hwang IC; Chang J; Park SM
PLoS One; 2017; 12(12):e0189114. PubMed ID: 29216279
[TBL] [Abstract][Full Text] [Related]
34. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.
Lochhead P; Hagan K; Joshi AD; Khalili H; Nguyen LH; Grodstein F; Chan AT
Gastroenterology; 2017 Oct; 153(4):971-979.e4. PubMed ID: 28728964
[TBL] [Abstract][Full Text] [Related]
35. Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study.
Chen CB; Lin M; Eurich DT; Johnson JA
Clin Ther; 2016 Jun; 38(6):1392-1400. PubMed ID: 27061884
[TBL] [Abstract][Full Text] [Related]
36. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis: risk of fractures with acid-suppressing medication.
Kwok CS; Yeong JK; Loke YK
Bone; 2011 Apr; 48(4):768-76. PubMed ID: 21185417
[TBL] [Abstract][Full Text] [Related]
39. Gastric Acid Suppressant Prophylaxis in Pediatric Intensive Care: Current Practice as Reflected in a Large Administrative Database.
Costarino AT; Dai D; Feng R; Feudtner C; Guevara JP
Pediatr Crit Care Med; 2015 Sep; 16(7):605-12. PubMed ID: 25901549
[TBL] [Abstract][Full Text] [Related]
40. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
